Ibrutinib may be a breakthrough for treatment of a rare lymphoma
Interim results confirmed the “unprecedented” single-agent activity of ibrutinib in relapsed or refractory mantle cell lymphoma.
Non-Hodgkin Lymphoma
FDA Update November/December 2012
Paclitaxel protein-bound particles for injectable suspension, 90-minute infusion of rituximab, omacetaxine mepesuccinate receive FDA approval
Higher risk of esophageal, stomach cancer with AIDS
Non-Hodgkin lymphoma rates down but carcinoma rates fairly constant from 1980 to 2007.
September: A month for cancer awareness
Patient information on coping with the emotional toll of cancer, making treatment decisions, dietary and nutritional needs, and survivorship care
Delayed methotrexate clearance
What are some common reasons for delayed methotrexate clearance after a 24-hour infusion?
Colorectal risk defined for childhood cancer survivors
Childhood cancer survivors may need earlier colorectal cancer screening, especially if abdominal radiation was part of their treatment.
Many women with cancer missing fertility risk info, services
Few women of childbearing age who are diagnosed with cancer are taking steps to preserve their fertility during treatment.
Blood cancers often require termination of early pregnancy
The urgent need for treatment may require a woman with a hematologic cancer to end an early-stage pregnancy, but not necessarily a later-stage one.
Stem cell treatment does not improve overall survival in follicular lymphoma
High-dose chemotherapy combined with autologous stem cell transplantation did not improve overall survival in previously untreated adult patients with follicular lymphoma.
Infusion reactions and immunotherapy for prostate cancer
This month’s questions: retreating with rituximab after an allergic reaction and administering the new prostate cancer immunotherapy.
Next post in Ask a Pharmacist
